Health Trials

New Onset Generalized Myasthenia Gravis (gMG)

1

Review clinical trials related to New Onset Generalized Myasthenia Gravis (gMG). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

The main purpose of this study is to measure how well adults with new-onset gMG (which means they've had generalized disease signs and/or symptoms for less than 1 year) respond to treatment with efgartigimod PH20 SC. The study consists of a treatment period of 51 weeks. The study duration for each participant will be approximately 58 weeks.

Participants needed: 30
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: argenxUpdated: Mar 10, 2026Locations: 18
Eligibility criteria

Is at least 18 years when signing the ICF [+5]

gMG diagnosis of MGFA class I or V [+2]

Read more